Introduction
Cellular interactions with the extracellular matrix maintain signaling pathways that suppress apoptosis (Giancotti and Tarone, 2003) . When outside their normal microenvironment, nontransformed cells undergo anoikis, a specific type of apoptosis that occurs when cells either lose contact with or form inappropriate cell-extracellular matrix interactions (Frisch and Francis, 1994) . This type of stress is encountered during cancer cell invasion into surrounding tissue and metastasis. Acquired resistance to apoptosis is a hallmark of cancer; however, the mechanisms by which oncogenes and/or loss of tumor suppressor genes mediate this resistance are poorly understood (Hanahan and Weinberg, 2000) .
In the intrinsic apoptotic pathway, cell fate is largely decided at the mitochondria by Bcl-2 family proteins that associate to either promote or inhibit apoptosis (Gross et al., 1999) . Anti-apoptotic members, such as Bcl-2, function in the outer mitochondrial membrane to heterodimerize with proapoptotic proteins and inhibit the function of the latter (Olivier et al., 1997; Cheng et al., 2001; Troppmair and Rapp, 2003) . Proapoptotic proteins can be subdivided into either multidomain or BH3-only proteins. Multidomain proapoptotic proteins function to permeabilize the outer mitochondrial membrane leading to the release of cytochrome c, formation of the apoptosome and activation of the caspase cascade. BH3-only proapoptotic proteins such as Bcl-2-interacting mediator of cell death (Bim) and Bcl-xL/Bcl-2-associated death promoter (Bad) activate multidomain proapoptotic proteins and/or inhibit antiapoptotic proteins (Cory and Adams, 2002; Letai, 2005) .
In 2002, mutations in the serine-threonine kinase, B-RAF, were identified in melanoma, thyroid cancer and colorectal cancer (Davies et al., 2002) . The most common mutation in B-RAF is a valine to glutamic acid substitution at residue 600 in the activation loop rendering B-RAF and the downstream Mitogenactivated protein/extracellular signal-regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway constitutively active. Mutant B-RAF can transform NIH3T3 fibroblasts and immortalized mouse melanocytes (Wellbrock et al., 2004) but may not be sufficient to initiate melanoma since benign nevus cells harbor B-RAF mutations (Dong et al., 2003) . However, B-RAF mutations correlate with melanoma progression as they have been detected in 75% of vertical growth phase tumors compared to 10% of radial growth phase tumors (Dong et al., 2003) . During vertical growth, cells invade from the epidermis or papillary dermis into the dermal layer where melanoma cells encounter and survive in the type I collagen-rich dermal microenvironment.
In our previous studies, we have shown that mutant B-RAF-harboring melanoma cells are susceptible to anoikis when B-RAF is depleted or MEK inhibited (Boisvert-Adamo and Aplin, 2006) . Cell survival of B-RAF-depleted melanoma cells was restored by adhesion to fibronectin, which is a minor matrix component of the dermis. However, the regulation of Bcl-2 family members and their role in B-RAF-mediated survival is poorly defined. A recent study showed that inhibition of MEK in melanoma cells leads to decreased serine-75 phosphorylation of Bad, consistent with increased Bad activity (Eisenmann et al., 2003) . The same study showed that the overexpression of S75A Bad was not sufficient to promote apoptosis unless MEK was inhibited. This suggests that other Bcl-2 family proteins are also involved in B-RAF-MEK-mediated cell survival in melanoma. Here, we show that coordinate regulation of multiple Bcl-2 family proteins, in particular, Bad and Bim, by B-RAF underlies resistance to anoikis in melanoma cells.
Results

Bad expression and phosphorylation are regulated by B-RAF-MEK signaling in melanoma cells
We have previously shown that mutant B-RAF protects human melanoma cells from anoikis (Boisvert-Adamo and Aplin, 2006) . To understand the mechanisms underlying B-RAF effects on cell survival we initially analysed the Bcl-2 family protein, Bad, that is phosphorylated by RSK1 at the inhibitory serine-75 residue in a MEK-dependent manner in melanoma cells (Eisenmann et al., 2003) . We utilized RNA interference to knockdown B-RAF and analysed phosphorylation and expression of Bad by western blotting. As expected, B-RAF expression and ERK1/2 phosphorylation were reduced following transfection of human B-RAF V600E -expressing WM793 melanoma cells with B-RAF-targeting siRNA (Figure 1a) . We previously showed that this B-RAF siRNA does not target C-RAF or A-RAF (Boisvert-Adamo and Aplin, 2006). Upon B-RAF knockdown, we detected reduced levels of serine-75 phosphorylated Bad and, interestingly, increased levels of Bad protein.
We also analysed the contribution of MEK, the main target of B-RAF activity. MEK was efficiently inhibited in WM793 cells by the addition of U0126 for 5 h, as determined by the loss of ERK1/2 phosphorylation ( Figure 1b ). Similar to B-RAF knockdown, Bad serine-75 phosphorylation was decreased and Bad protein levels increased following MEK inhibition. Similar effects on Bad phosphorylation and expression were observed following MEK inhibition in vertical growth phase WM115 cells that harbor mutant B-RAF V600D (Davies et al., 2002; Supplementary Figure 1) . Thus, B-RAF-MEK regulation of Bad is observed in more than one melanoma cell line.
Regulation of Bad by phosphorylation and sequestration has been well documented (Zha et al., 1996; Datta et al., 1997) ; however, the regulation of Bad expression is largely unknown. Thus, we determined the level at which this regulation occurs. By real-time quantitative RT-PCR (qRT-PCR) analysis, we found that Bad mRNA levels were increased 2-to 2.5-fold following B-RAF depletion or MEK inhibition in WM793 cells, respectively (Figures 1c and d) . In addition, we found that treatment with the transcriptional inhibitor, actinomycin D, blocked the increase in Bad mRNA levels following short-term (5 h) MEK inhibition (Figure 1e ), suggesting that B-RAF-MEK signaling regulates Bad at the transcriptional level. In summary, inhibition of B-RAF-MEK signaling alters Bad phosphorylation and expression in WM793 melanoma cells.
Expression of Bad is sufficient to induce apoptosis in nonadherent melanoma cells Since Bad is a proapoptotic Bcl-2 family protein (Yang et al., 1995) , we determined if expression of Bad was sufficient to induce apoptosis in adherent and suspended melanoma cells. We utilized lentiviruses to generate stable WM793 cell populations expressing either beta galactosidase (LacZ), wild-type Bad or S75A Bad. Expression of the appropriate transgene was demonstrated by western blot analysis (Figure 2a ). Cells were transfected with either control or B-RAF siRNA, plated on fibronectin or in suspension on agar-coated dishes for 48 h and analysed for cleaved caspase-3 staining, a marker for apoptosis, by flow cytometry. Bad-expressing cells replated onto fibronectin did not display enhanced cleaved caspase-3 staining (Figures 2b and c) . In suspension, knockdown of B-RAF induced caspase-3 cleavage in approximately 60% of the LacZ control cells (Figures 2b and c) , similar to the parental WM793 cells (Boisvert-Adamo and Aplin, 2006) . Ectopic expression of either wild-type Bad or S75A Bad caused a fourfold increase in the percentage of cells staining positive for cleaved caspase-3 in the absence of B-RAF knockdown although not to the level of that achieved with B-RAF knockdown. These data indicate that the overexpression of Bad is sufficient to promote apoptosis in suspended but not adherent WM793 cells.
Increased Bad levels in B-RAF-depleted melanoma cells are partially responsible for susceptibility to anoikis We next determined whether the increased Bad expression was necessary for the decreased resistance to anoikis in B-RAF knockdown cells. WM793 cells were transfected with either control, Bad or B-RAF siRNA alone, or with B-RAF and Bad siRNAs in combination. Transfected cells were cultured in suspension and after 48 h were stained for cleaved caspase-3. Transfection with Bad siRNA decreased Bad expression in B-RAF knockdown cells (Figure 3a ) without altering levels of p53 up-regulated modulator of apoptosis (PUMA), another BH3-only protein (data not shown). Importantly, the knockdown reduced Bad expression to levels comparable to control cells. Co-knockdown of Bad with B-RAF significantly reduced the percentage of cleaved caspase-3-positive cells compared to B-RAF knockdown alone (Figures 3b and c) . However, decreasing Bad levels was not sufficient to completely reverse the effects of B-RAF knockdown. Similar results were obtained utilizing a second siRNA sequence to target Bad (Supplementary Figure 2) . These results together with ectopic expression experiments indicate that Bad is partially responsible for increased susceptibility to anoikis in B-RAF knockdown cells.
Bim EL expression is regulated by B-RAF-MEK signaling in melanoma cells
Bim is another proapoptotic Bcl-2 family member and is negatively regulated by MEK-ERK signaling in fibroblasts, epithelial and lymphoma cells Luciano et al., 2003; Reginato et al., 2003) . To determine if Bim is regulated by B-RAF-MEK signaling in melanoma cells, we analysed Bim protein levels in B-RAF knockdown WM793 cells by western blotting. B-RAF knockdown and the subsequent decrease in phospho-ERK1/2 levels was associated with an approximately fivefold increase in Bim EL protein levels (Figures 4a and b) . Additionally, Bim EL migrated faster following B-RAF knockdown, consistent with decreased phosphorylation, as reported previously Luciano et al., 2003; Weston et al., 2003; Marani et al., 2004) . Similarly, inhibition of MEK with the pharmacological inhibitor U0126 caused a time- (Figure 4c ) and a dose-dependent increase in Bim EL levels ( Figure 4d) . Overexposure of the Bim blot demonstrates that other Bim isoforms, Bim L and Bim S , were not upregulated following MEK inhibition (Figure 4e ). Bim EL expression was also upregulated following U0126 treatment of WM115 cells (Supplementary Figure 1) . These data demonstrate that inhibition of B-RAF-MEK signaling promotes the expression of Bim EL in melanoma cells.
Bim EL is regulated by the proteasome Bim EL has been shown to be regulated by MEK-ERK1/ 2 signaling at both the transcriptional and posttranslational levels Luciano et al., 2003; Reginato et al., 2003; Weston et al., 2003; Marani et al., 2004) . Although we detected an increase in the level of Bim mRNA upon either B-RAF knockdown or MEK inhibition ( Supplementary Figures 3a and b) , we did not observe an increase in the expression of Bim L and Bim S isoforms at the protein level ( Figure 4e ). It has been shown that these three Bim isoforms are produced Bim has also been shown to be degraded by the proteasome upon MEK-ERK-dependent phosphorylation at serine-69 that is present in Bim EL but not Bim L or Bim S (Bouillet et al., 2001; Luciano et al., 2003; Weston et al., 2003) . Since we detected enhanced mobility of Bim EL upon B-RAF-MEK inhibition consistent with a lack of phosphorylation, we tested for proteasomal regulation of Bim EL in WM793 cells. Upon treatment of WM793 cells with either of two proteasomal inhibitors, MG132 and ALLN, the levels of Bim EL were increased (Figure 5a ). Furthermore, Bim EL protein turnover in the absence of new protein synthesis was dramatically reduced following MEK inhibition ( Figure 5b ). Consistent with phosphorylation of Bim EL being important for Bim protein turnover Luciano et al., 2003; Reginato et al., 2003; Weston et al., 2003; Marani et al., 2004) , mutant S69A Bim EL was expressed at higher levels and displayed increased mobility compared to wild-type Bim EL in WM793 cells ( Figure 5c ). Also, consistent with these previous studies on Bim EL turnover, additional MEK-dependent phosphorylation sites may be present in Bim EL since treatment with U0126 further enhanced the mobility of the mutant S69A Bim EL . However, U0126 treatment was able to enhance expression of wild-type Bim EL but had little effect on levels of S69A Bim EL . These results demonstrate that B-RAF signaling regulates Bim EL protein turnover in melanoma cells.
Induction of Bim EL renders cells sensitive to anoikis WM793 cells stably expressing Bim EL did not show increased sensitivity to anoikis (data not shown), perhaps due to adaptations achieved during antibiotic selection to allow for survival in the presence of exogenous Bim. Therefore, we generated WM793 cell populations expressing either wild-type Bim EL , S69A Bim EL or LacZ under the regulation of tetracycline. Tetracycline induction and correct expression were B-RAF V600E regulation of cell survival in melanoma K Boisvert-Adamo and AE Aplin determined by western blotting (not shown). As expected, wild-type Bim EL is expressed at a lower level than S69A Bim EL upon induction with tetracycline and was not detected in the tetracycline-inducible LacZ cell lines (Figure 6a ). Inhibition of MEK by treatment with U0126 further increased the tetracycline-induced expression of wild-type Bim EL to a level similar to that of tetracycline-induced S69A Bim EL .
To determine if the induced expression of Bim EL was sufficient to promote sensitivity to anoikis, we analysed caspase-3 cleavage by flow cytometry. Induction of Bim EL expression did not induce apoptosis in cells replated onto fibronectin (Figures 6b and c) . In suspension conditions, the percentage of LacZ cells expressing cleaved caspase-3 remained unaltered upon the addition of tetracycline but was increased following B-RAF knockdown (Figures 6b and c) . Addition of tetracycline to wild-type Bim EL -and S69A Bim ELinducible cells caused a fourfold increase in the percentage of cells staining positive for cleaved caspase-3, statistically significant increases compared to noninduced cells of the same cell population or induced LacZ cells. Together, these data show that Bim EL expression is sufficient to increase sensitivity to anoikis in melanoma cells. However, B-RAF knockdown yielded higher levels of apoptosis than Bim EL expression and the enhanced expression of S69A Bim EL did not further enhance apoptosis above levels seen with wild-type Bim EL . These data indicate that increased Bim expression alone does not appear to be responsible for all B-RAF effects. B-RAF V600E regulation of cell survival in melanoma K Boisvert-Adamo and AE Aplin RNA interference for Bim was decreased upon attempt of triple knockdown with B-RAF, Bim and Bad siRNAs. Therefore, we constructed a Bim shorthairpin RNA (shRNA) lentivirus and generated stable Bim shRNA-expressing WM793 cells to deplete Bim (Figure 8a ). SiRNAs were utilized to transiently knock down B-RAF, Bad or both B-RAF and Bad in both control and Bim shRNA cells. Approximately 70% of control shRNA cells stained positively for cleaved caspase-3 following B-RAF knockdown; however, staining in B-RAF knockdown cells was attenuated in the Bim shRNA cell line to approximately 40% (Figures 8b and c) . This further indicates a necessity for Bim in anoikis in B-RAF knockdown cells. Importantly, the percentage of cleaved caspase-3-positive cells in Bim shRNA cells following B-RAF knockdown was further reduced to approximately 20% with additional knockdown of Bad. Complete inhibition to the basal levels was not achieved perhaps due to either incomplete knockdown of Bim or the contributions of another apoptotic regulator.
To complement cleaved caspase-3 staining, we performed propidium iodide analysis of sub-G 1 cells. In nonadherent conditions, control knockdown populations showed a low level of sub-G 1 cells, but sub-G 1 levels were markedly enhanced following B-RAF knockdown (Figure 8d ). While Bim co-knockdown with B-RAF partially reversed this effect, combined Bim and Bad knockdown with B-RAF showed sub-G 1 levels close to control knockdown populations. The levels of sub-G 1 cells following B-RAF knockdown were similar to our published terminal transferase dUTP nick-end labeling staining data (Boisvert-Adamo and Aplin, 2006) and were lower than percentages for cleaved caspase-3 staining since the latter is an early marker of apoptosis. Together, these data clearly demonstrate a major role for Bad and Bim in the regulation of apoptosis downstream of B-RAF in melanoma cells.
Previously, our laboratory has demonstrated that B-RAF knockdown can inhibit cyclin D1 expression and cell cycle progression and that depletion of cyclin D1 induces cell cycle arrest (Bhatt et al., 2005 (Bhatt et al., , 2007 . Since cell cycle arrest can induce apoptosis, we determined if cyclin D1 depletion induced sensitivity to anoikis. In contrast to B-RAF knockdown, cyclin D1 knockdown failed to promote the cleavage of caspase-3 on agar (Supplementary Figure 4a) . In addition, the depletion of cyclin D1 did not increase expression of Bad or Bim (Supplementary Figure 4b) . Together, these data suggest that anoikis sensitivity induced upon B-RAF knockdown is not due to a secondary effect of cell cycle arrest.
Discussion
Identifying the mechanisms underlying oncogenemediated resistance to anoikis is of critical importance. In this study, we demonstrate that B-RAF coordinately B-RAF V600E regulation of cell survival in melanoma K Boisvert-Adamo and AE Aplin regulates two proapoptotic proteins, Bad and Bim, which render melanoma cells susceptible to anoikis. Interestingly, these two proapoptotic proteins are differentially regulated by B-RAF. Bad is controlled at the mRNA level, while Bim EL is regulated mainly at the level of protein stability. Therefore, this study describes mechanisms by which a common oncogene, B-RAF, promotes resistance to anoikis, a hallmark of malignant cancer cells. We have previously shown that mutant B-RAF protects melanoma cells from anoikis (Boisvert-Adamo and Aplin, 2006) . To understand the mechanism underlying this effect, we initially analysed Bad, a BH3-only proapoptotic protein. Inhibition of MEK-ERK-RSK signaling leads to decreased Bad serine-75 phosphorylation (Eisenmann et al., 2003) , which releases Bad from 14-3-3 binding and cytosolic sequestration (Zha et al., 1996) . Eisenmann et al. (2003) also found that overexpression of a S75A mutant Bad was not sufficient to promote apoptosis in adherent melanoma cells, although it did increase the percentage of cells undergoing apoptosis when MEK was pharmacologically inhibited. We extend these findings in several ways. First, we show that Bad serine-75 phosphorylation is dependent on B-RAF in melanoma cells. Second, we observe upregulation of Bad protein and mRNA levels following inhibition of B-RAF-MEK signaling. Although Bad has been demonstrated to be transcriptionally regulated by PI-3 kinase (Cowburn et al., 2002) and p53 signaling (Jiang et al., 2006) , our data represent the first evidence for MEK-ERK regulation of Bad mRNA levels. Third, we show that Bad is partially required for susceptibility to anoikis following B-RAF knockdown and is sufficient to induce apoptosis in nonadherent melanoma cells. In our studies, wild-type Bad and S75A Bad were equivalent in their proapoptotic activity indicating that the level of expression of wildtype Bad may be sufficient to overcome 14-3-3 inhibition that sequesters phosphorylated Bad.
Our findings and those of Eisenmann et al. clearly indicate the existence of B-RAF-regulated mechanisms in addition to the control of Bad. Since studies have shown Bim, another BH3-only proapoptotic protein, to be regulated by MEK-ERK signaling, we analysed Bim for regulation by B-RAF in melanoma cells. Bim is known to be regulated by MEK-ERK signaling at both the transcriptional (Reginato et al., 2003; Weston et al., 2003) and post-translational levels Luciano et al., 2003; Weston et al., 2003; Marani et al., 2004) . The mechanism for ERK-mediated transcriptional regulation of Bim is unknown, whereas ERKmediated phosphorylation of Bim on serine-69, a site present in Bim EL but not the Bim S or Bim L isoforms, promotes proteasomal-mediated degradation. Our results demonstrate that a major mechanism of B-RAF-MEK regulation of Bim EL in melanoma cells is via promoting its proteasomal degradation. Bad levels were not increased following proteasomal inhibition (data not shown); thus, Bim and Bad are differentially regulated in melanoma cells.
Our work shows a requirement for Bim EL , in combination with Bad, to render B-RAF knockdown melanoma cells susceptible to anoikis. Alterations in Bim EL levels have previously been shown to enhance sensitivity to anoikis in breast epithelial and keratinocyte cell lines (Fukazawa et al., 2002; Wang et al., 2004; Quadros et al., 2006) . Another study showed that the Bim EL expression is adhesion dependent and induces anoikis (Reginato et al., 2003) . Our data show that Bim EL is upregulated following B-RAF knockdown in both adherent and nonadherent cells (data not shown), consistent with our previous report that ERK1/2 activity is adhesion independent in melanoma cells (Conner et al., 2003) .
Recently, trials with the proteasomal inhibitor bortezomib have demonstrated that inhibition of the proteasomal system in combination with conventional chemotherapy gives an additive or synergistic activity in multiple myeloma patients (Kropff et al., 2005; Berenson et al., 2006) . Bortezomib causes apoptosis in melanoma cells via upregulation of the BH3-only protein, NOXA or via activation of nuclear factor-kB (Amiri et al., 2004; Qin et al., 2005) . Nevertheless, the inhibition of Bim proteasomal degradation may also be an important factor in sensitizing cancer cells to apoptosis. Clearly, it will be important to determine the E3 ubiquitin ligase that regulates Bim protein turnover in melanoma cells. Studies in osteoclasts show that the RING-finger E3 ubiquitin ligase, c-Cbl, can be coimmunoprecipitated with Bim and that the overexpression of c-Cbl is associated with increased Bim ubiquitylation and decreased Bim protein levels (Akiyama et al., 2003) . Another group was able to detect an increase in Bim EL protein in the testis of Cbl knockout mice but were unable to coimmunoprecipitate Bim EL and Cbl (El Chami et al., 2005) , indicating that c-Cbl regulation of Bim EL may not be direct. In melanoma cells, we were unable to confirm a role for c-Cbl in the regulation of Bim EL since efficient knockdown of c-Cbl did not increase Bim EL protein levels (Supplementary Figure 5) . Thus, identifying the specific E3 ligase responsible for targeting Bim EL to the proteasomal system may aid in the development of future therapies for melanoma and other cancers that depend upon Bim EL for induction of apoptosis.
In summary, we show that B-RAF-MEK signaling downregulates two proapoptotic proteins, Bad and Bim, in melanoma cells by different mechanisms. We also demonstrate that Bad and Bim are major regulators that promote sensitivity to anoikis in B-RAF-depleted melanoma cells. Future studies will focus on identification of the specific E3 ligase-regulating Bim degradation and on determining the mechanism regulating Bad transcription by B-RAF-MEK signaling.
Materials and methods
Cell culture conditions Human WM793 and WM115 melanoma cells were cultured in MCDB 153 containing 20% Leibovitz's L-15 medium, 2% fetal bovine serum and 5 mg ml À1 insulin. For apoptosis assays, cells were replated onto either 10 mg ml À1 fibronectin or 2% bactoagar for 48 h in serum-free MCDB 153 medium containing 0.5% bovine serum albumin (BSA). Cells were then processed for western blot analysis or measurement of apoptosis.
Antibodies and inhibitors
The following antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA): anti-Bad (no. 9292), anti-phospho-Bad (S112, no. 9296), anti-cleaved caspase-3 (no. 9661) and anti-phospho-ERK (Thr202/Tyr204, no. 4377). Anti-ERK1/2 (sc1647) and anti-B-RAF (sc5284) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Bim (AAP-330) was purchased from Stressgen (Ann Arbor, MI, USA). The MEK inhibitor U0126 was purchased from Cell Signaling Technology, and MG132 and ALLN inhibitors were from Calbiochem (La Jolla, CA, USA). Cycloheximide was purchased from Sigma (St Louis, MO, USA).
siRNA transfections WM793 cells were transfected with siRNAs using Oligofectamine (Invitrogen, Carlsbad, CA, USA). The following siRNAs (Dharmacon, Lafayette, CO, USA) were utilized at 25 nM: nontargeting control: UAGCGACUAAACACAUCAAUU, B-RAF: ACAGAGACCUCAAGAGUAAUU, Bad: CAGA GUUUGAGCCGAGUGAUU (all from Dharmacon) and Bim: GACCGAGAAGGUAGACAAUUGTT and CAAUU GUCUACCUUCUCGGUCTT (Cell Signaling Technology). Cells were serum-starved for a further 16 h and either replated on agar-coated dishes for apoptosis assays or lysed for western blot analysis, 72 h post-transfection.
Western blotting
Whole-cell lysates were prepared and processed as previously described (Boisvert-Adamo and Aplin, 2006) . Chemiluminescence was detected using the Fluor-S Multi-Imager (Bio-Rad, Hercules, CA, USA) and quantitated using Quantity One software.
Apoptosis assays
For analysis of cleaved caspase-3, trypsinized cells were fixed in 4% methanol-free formaldehyde and permeabilised in methanol overnight. Cells were then washed in phosphatebuffered saline (PBS)/0.5% BSA, blocked in the same buffer and incubated with anti-cleaved caspase-3 antibody for 1 h at 4 1C. scatter to differentiate the cells from debris and 1 Â 10 4 cells were counted for each condition. Data were plotted on a histogram as mean fluorescent intensity versus cell number.
For sub-G 1 analysis, knockdown cells were fixed in ice-cold 70% ethanol and permeabilized with 0.1% Triton X-100 and 100 mg ml À1 RNaseA in PBS at 37 1C for 2 h. DNA was stained with 50 mg ml À1 of propidium iodide at 37 1C for 15 min. Cells were analysed by FACSCanto (Becton Dickinson Biosciences).
qRT-PCR Seventy-two hours post knockdown, or following 5 h of U0126 treatment, total RNA was extracted from melanoma cells using the Versagene RNA purification kit (Gentra Systems, Minneapolis, MN, USA) and processed for qRT-PCR, as previously described (Bhatt et al., 2007) . Actinomycin D (1 mg ml
À1
) was utilized, 30 min prior to U0126 treatment where indicated. The primers used were: actin forward (TACCT CATGAAGATCCTCACC), reverse (TTTCGTGGATGCCA CAGGAC), and Bad forward (CCCAGAGTTTGAGCCGA GTG), reverse (CCCATCCCTTCGTCGTCCT). Reactions were performed using SYBR Green mix and the MyiQ RealTime PCR detection system (Bio-Rad). Reaction conditions were: denaturation at 94 1C for 30 s; annealing at 50 1C for 30 s and elongation at 72 1C for 30 s; 40 cycles in total. Relative mRNA levels were calculated using the comparative C t method (DC t ) (Pfaffl, 2001 ).
Cloning
Wild-type and S75A Bad human cDNAs were a kind gift from Matthew VanBrocklin and Dr George Vande Woude (Van Andel Research Institute, MI, USA) (Eisenmann et al., 2003) . Wild-type and S69A Bim human cDNAs were donated by Dr Hidesuke Fukazawa (National Institute of Infectious Diseases, Tokyo, Japan) (Fukazawa et al., 2004) . Inserts in the pENTR/ 3C vectors (Bad) or pDONR201 (Bim) were verified by DNA sequencing and subsequently recombined with pLenti4/V5-DEST (Bad), pLenti6/UbC/V5-DEST (Bim EL constitutive) or pLenti4/TO/V5-DEST (Bim EL inducible) using the LR Clonase II kit and protocol (Invitrogen). Stop codons from cDNAs were maintained to omit the inclusion of a V5 epitope tag contained within the vectors.
Bim shRNA was generated using the BLOCK-iT RNAi Designer system (Invitrogen). The sequences for the Bim shRNA oligos are as follows: 5 0 -CACCGGTTATCTTAC GACTGTTATTCAAGAGATAACAGTCGTAAGATAACC and 5 0 -AAAAGGTTATCTTACGACTGTTATCTCTTGAA TAACAGTCGTAAGATAACC. Oligos were annealed and ligated into the pENTR/H1/TO vector (Invitrogen) and analysed for errors by DNA sequencing. Correct constructs were then recombined into the pLenti4/BLOCK-iT-DEST vector (Invitrogen).
Stable cell lines
LacZ, wild-type Bim, S69A Bim, wild-type Bad or S75A Bad pDEST vectors or control or Bim shRNA vectors were transfected along with the packaging plasmids pLP1, pLP2 and pLP/VSV-G into 293 FT cells using FuGENE 6 Transfection Reagent (Roche Diagnostic Co., Indianapolis, IN, USA) according to the manufacturer's protocol. Medium was replaced after 24 h and the virus-containing media were collected after a further 24 h. WM793 cells were transduced with lentivirus and 48 h following transduction, antibiotic selection using either blasticidin (constitutive Bim cDNA) or zeocin (Bad cDNA, Bim shRNA) was carried out for 2 weeks. Stable expression of each transgene was analysed by western blotting. In the case of inducible Bim EL , WM793 cells that stably express the tetracycline repressor were transduced with pLenti4/TO/LacZ or pLenti4/TO/Bim EL S69A viral supernatants and cell populations generated by selection with zeocin. Inducible expression of the transgene was obtained by treatment of cultures with tetracycline at a final concentration of 1 mg ml
À1
.
